Improving CNS penetration of radiolabeled TKI PET tracers through PgP/BCRP inhibition - M14EEP:Improving CNS uptake of TKI PET tracers through PgP/BCRP inhibition

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 7 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•The study population consists of cancer patients with advanced or metastatic solid tumors for whom no standard therapy is available or for whom a TKI which is a PgP/BCRP substrate is a standard therapeutic option (erlotinib, sunitinib, imatinib, gefitinib, sorafenib, lapatinib, crizotinib, vemurafenib).

•Known brain metastases;
•Patients who have had previous treatment with central nervous system irradiation;
•Treatment with the tyrosine kinase inhibitor used as TKI PET tracer within three half lives before the PET scans;
•Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance;.
•Patients are not allowed to use co-medication with PgP or BCRP modulators (including OTC medication).
•Patients are also not allowed to use co-medication which are PgP or BCRP substrates as this may lead to increased toxicity.
•Known hypersensitivity to erlotinib, elacridar or any excipients used in the formulation of either IMPs.
•Known contra-indications for a MRI scan.

发起方

Antoni van Leeuwenhoek Ziekenhuis